Aankondiging • Apr 03
Amyris, Inc. announced delayed annual 10-K filing On 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Aankondiging • Jan 24
Third Amended Joint Reorganization Plan Filed by Amyris, Inc. Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Aankondiging • Jan 06
Foris Ventures Provides Information to the Shareholders On January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets. Aankondiging • Dec 28
Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024 Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities. Aankondiging • Nov 14
Amyris, Inc. announced delayed 10-Q filing On 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Aankondiging • Sep 08
Nasdaq to Delist the Common Stock of Amyris On September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time. Aankondiging • Sep 02
Amyris, Inc. Appoints Scott White as A Class II Director On August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University. Aankondiging • Aug 12
Amyris' Common Stock To Be Delisted from Nasdaq As previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. Aankondiging • May 29
Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement On May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split. Breakeven Date Change • Apr 17
No longer forecast to breakeven The 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025. Breakeven Date Change • Apr 01
No longer forecast to breakeven The 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025. Breakeven Date Change • Mar 25
No longer forecast to breakeven The 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$77.9m in 2025. Breakeven Date Change • Mar 18
No longer forecast to breakeven The 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025. Breakeven Date Change • Mar 03
Forecast to breakeven in 2025 The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule. Breakeven Date Change • Feb 17
Forecast to breakeven in 2025 The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule. Aankondiging • Jan 31
Amyris Launches 4U by Tia™ Haircare Line Exclusively At Walmart Amyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day. Breakeven Date Change • Jan 24
Forecast to breakeven in 2025 The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$114.3m in 2025. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Breakeven Date Change • Dec 19
No longer forecast to breakeven The 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024. Breakeven Date Change • Nov 28
No longer forecast to breakeven The 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024. Breakeven Date Change • Oct 20
Forecast to breakeven in 2024 The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule. Recent Insider Transactions • Sep 08
Chief Legal Officer & Secretary recently sold Mex$287k worth of stock On the 2nd of September, Nicole Kelsey sold around 5k shares on-market at roughly Mex$57.25 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger sale from another insider worth Mex$2.4m. Insiders have been net sellers, collectively disposing of Mex$1.5m more than they bought in the last 12 months. Recent Insider Transactions • Aug 18
President recently bought Mex$1.4m worth of stock On the 15th of August, John Melo bought around 17k shares on-market at roughly Mex$80.06 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by Mex$1.1m. Breakeven Date Change • Aug 11
Forecast to breakeven in 2024 The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule. Reported Earnings • Aug 10
Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021) Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91% compared to a 2.5% decline forecast for the industry in Mexico. Recent Insider Transactions • Jul 09
President recently sold Mex$2.4m worth of stock On the 6th of July, John Melo sold around 56k shares on-market at roughly Mex$44.05 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months. Recent Insider Transactions • Jun 06
CFO & Chief Administration Officer recently sold Mex$1.6m worth of stock On the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly Mex$45.73 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by Mex$8.8m. Board Change • Feb 18
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 03
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Ana Dutra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jan 08
Forecast to breakeven in 2024 The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Breakeven Date Change • Jan 01
Forecast to breakeven in 2024 The 6 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$78.6m in 2024. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Recent Insider Transactions • Dec 12
Independent Director recently bought Mex$2.1m worth of stock On the 6th of December, James McCann bought around 17k shares on-market at roughly Mex$121 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold Mex$41m more in shares than they bought in the last 12 months. Reported Earnings • Nov 10
Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.37 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$47.9m (up 40% from 3Q 2020). Net loss: US$32.9m (loss narrowed 61% from 3Q 2020). Recent Insider Transactions • Sep 05
CFO & Chief Administration Officer recently sold Mex$7.2m worth of stock On the 2nd of September, Hermanus Kieftenbeld sold around 24k shares on-market at roughly Mex$297 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$30m. This was Hermanus' only on-market trade for the last 12 months. 
